SlideShare una empresa de Scribd logo
1 de 9
Cardiobesity Unravelling the mechanistic link between obesity, metabolic disorders and cardiovascular disease Jacqueline de Graaf  Ko Willems van Dijk
Cardiobesity Consortium Name Institute Genetics Clinical pheno- typing In vitro  analysis Animal model Systems Biology Cohorts Intervention Prof. C. van Duijn  ErasmusMC X X Prof. J. de Graaf UMCN X X X Dr.  K. Willems van Dijk LUMC X X Prof. M. Hofker UMCG X X X X Prof. E. Feskens WUR X X X Prof. P. Slagboom LUMC X X Prof. C. Stehouwer MUMC X X Dr. B. van Ommen TNO X Prof. T. Hankemeier UL X
Is it possible to identify those overweight individuals who are prone to developing cardiovascular disease?  Cardiobesity Health care problem Age Gender Mechanisms We will reveal  novel genes and markers for improved risk stratification, personalized prevention, and new therapeutic options to decrease the CVD burden in the overweight Obesity Metabolic disorders CVD
Cardiobesity Research questions What markers/parameters identify those overweight subjects at increased risk for metabolic disorders and CVD WP 6  Genomics platforms and system biology What molecular mechanisms, especially in adipose tissue, are responsible for increased risk for metabolic disorders and CVD? WP1 Genetics WP2 Clinical phenotype WP 4 Molecular mechanisms WP3 Adipose tissue functionality WP 5  Cohorts / Intervention trials  Novel candidate genes and markers for CV risk stratification and personalized prevention in overweight individuals
Integrated data warehousing Bioinformatics and biostatistics System biology Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Leiden Longevity Cohort Aging cohort with low cardiometabolic risk 420 families – 3500 subjects Available data: GWAS (n=3500) Sequence data (n=220) Metabolomics (n=3500)  Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Whole exome sequencing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  CT, MRI, DEXA Obesity-imaging Nail fold capillaroscopy Retinography Endothelial Glycocalyx  Micro-vascular imaging IMT, PWV, ABI, Plaques MRI, PET/CT, CEUS  for vulnerable plaques Macro-Vascular imaging  Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Adipose tissue biopsies Ex vivo and in vitro Inflammasome Nod like receptors Immune cells Transcriptomics Metabolomics Proteomics  Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals  Nijmegen Biomedical Study N=1517  ERF and Rotterdam study N=3000 and n=12.000 Maastricht study and CODAM N= 6000 and n=574 LifeLines n>50.000 Leiden Longevity Study  Trial n=60 EetMeetWeet N=300 Familial Combined Hyperlipidemia N=687 – 70 families Overweight Metabolic Disorders Premature CVD  WP1: Genetics Whole exome sequencing WP3: Adipose tissue characterization In vitro analyses WP6: Genomics analysis platforms Transcriptomics, metabolomics, proteomics WP2: Obesity and vascular imaging In depth clinical phenotyping Candidate mechanisms  linking obesity with CVD WP6: Systems Biology Data integration and interpretation WP4:Mouse models Mechanistic studies Leiden Longevity Cohort N=3500 – 420 families Metabolic health CVD protection Large cohorts Selection of  overweight subjects - with/without CVD - with and without metabolic disorders  WP5:  Epidemiology Validation in large cohorts N>75.000 and by interventions Novel genes and markers for CV risk stratification and personalized prevention in overweight individuals
Cardiobesity Translation axis Patients: FCH, LLS, cohort subsets Basic and translational research Genetics Clinical phenotyping Systems biology Adipose tissue studies Mouse models Candidate mechanisms:  Linking obesity and CVD Epidemiology:  Cohorts and interventions Novel candidate genes and markers for CVD risk stratification and personalized prevention in overweight individuals
Focus areas  Dutch  Heart Foundation:  Aging  Gender  Metabolic disorders Cardiobesity Focus areas Obesity Metabolic disorders CVD Age Gender Mechanisms
Cardiobesity consortium Unique in combining expertise in basic, clinical and epidemiological research resulting in integrated approach to link obesity to CVD Collaboration with (inter)national consortia:  ‘ Complementary and confirmatory replication’ GoNL – BBMRI – NCHA – CHANCES – IDEAL – EAGLE EPI2  - CTMM ‘predict’ - NCSB – CMSB2 – NMC  Cardiobesity (Inter)national perspectives
To identify those overweight individuals who are prone to develop  cardiovascular disease by revealing the mechanisms linking obesity to CVD  Cardiobesity Age Gender Mechanisms Obesity Metabolic disorders CVD

Más contenido relacionado

La actualidad más candente

Cardiovasc diabetol 2009_sep_26_8_52[1]
Cardiovasc diabetol 2009_sep_26_8_52[1]Cardiovasc diabetol 2009_sep_26_8_52[1]
Cardiovasc diabetol 2009_sep_26_8_52[1]
Manuel F. Miyamoto
 
Metabolic syndrome in Community Medicine
Metabolic syndrome in Community Medicine Metabolic syndrome in Community Medicine
Metabolic syndrome in Community Medicine
Dr. Anees Alyafei
 
Ueda2015 dm cancer_dr.hala aly
Ueda2015 dm  cancer_dr.hala alyUeda2015 dm  cancer_dr.hala aly
Ueda2015 dm cancer_dr.hala aly
ueda2015
 

La actualidad más candente (19)

Focusing on 12 gm Haemoglobin for Children, Girls & Women in INDIA : Dr Shard...
Focusing on 12 gm Haemoglobin for Children, Girls & Women in INDIA : Dr Shard...Focusing on 12 gm Haemoglobin for Children, Girls & Women in INDIA : Dr Shard...
Focusing on 12 gm Haemoglobin for Children, Girls & Women in INDIA : Dr Shard...
 
Kawita bapat BRCA
Kawita bapat BRCA Kawita bapat BRCA
Kawita bapat BRCA
 
Cardiovasc diabetol 2009_sep_26_8_52[1]
Cardiovasc diabetol 2009_sep_26_8_52[1]Cardiovasc diabetol 2009_sep_26_8_52[1]
Cardiovasc diabetol 2009_sep_26_8_52[1]
 
Metabolic syndrome in Community Medicine
Metabolic syndrome in Community Medicine Metabolic syndrome in Community Medicine
Metabolic syndrome in Community Medicine
 
Sitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.xSitagliptina e proteção em ca diferenciado da tireóide.x
Sitagliptina e proteção em ca diferenciado da tireóide.x
 
Stem cell therapies - a special case of therapy and research
Stem cell therapies - a special case of therapy and research Stem cell therapies - a special case of therapy and research
Stem cell therapies - a special case of therapy and research
 
Polycystic Ovary Syndrome A Review
Polycystic Ovary Syndrome A ReviewPolycystic Ovary Syndrome A Review
Polycystic Ovary Syndrome A Review
 
Cancer and Diabetes
Cancer and DiabetesCancer and Diabetes
Cancer and Diabetes
 
Diabetes and cancer 2015 march
Diabetes and cancer 2015 marchDiabetes and cancer 2015 march
Diabetes and cancer 2015 march
 
Inés Barroso-Lo último en obesidad
Inés Barroso-Lo último en obesidadInés Barroso-Lo último en obesidad
Inés Barroso-Lo último en obesidad
 
Journal club
Journal clubJournal club
Journal club
 
Diet and physical activity in preventing cancer
Diet and physical activity in preventing cancerDiet and physical activity in preventing cancer
Diet and physical activity in preventing cancer
 
Post-diagnosis hemoglobin change associates with overall survival of multiple...
Post-diagnosis hemoglobin change associates with overall survival of multiple...Post-diagnosis hemoglobin change associates with overall survival of multiple...
Post-diagnosis hemoglobin change associates with overall survival of multiple...
 
Tips on how to preven prostate cancer(1)
Tips on how to preven prostate cancer(1)Tips on how to preven prostate cancer(1)
Tips on how to preven prostate cancer(1)
 
Resurge - The Godzilla Of Offers - Resurge weight loss.
Resurge - The Godzilla Of Offers - Resurge weight loss.Resurge - The Godzilla Of Offers - Resurge weight loss.
Resurge - The Godzilla Of Offers - Resurge weight loss.
 
Chronic Graft versus Host Disease - risk factors, pattern and transplant outc...
Chronic Graft versus Host Disease - risk factors, pattern and transplant outc...Chronic Graft versus Host Disease - risk factors, pattern and transplant outc...
Chronic Graft versus Host Disease - risk factors, pattern and transplant outc...
 
04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel
 
Ueda2015 dm cancer_dr.hala aly
Ueda2015 dm  cancer_dr.hala alyUeda2015 dm  cancer_dr.hala aly
Ueda2015 dm cancer_dr.hala aly
 
Nrgastro.2012.208
Nrgastro.2012.208Nrgastro.2012.208
Nrgastro.2012.208
 

Destacado (6)

Variant Calling II
Variant Calling IIVariant Calling II
Variant Calling II
 
Peripheral Neurological Disorders & Central Nervous Center
Peripheral Neurological Disorders & Central Nervous CenterPeripheral Neurological Disorders & Central Nervous Center
Peripheral Neurological Disorders & Central Nervous Center
 
Ngs ppt
Ngs pptNgs ppt
Ngs ppt
 
Can we exploit the power of NGS to move towards personalized medicine?, Cente...
Can we exploit the power of NGS to move towards personalized medicine?, Cente...Can we exploit the power of NGS to move towards personalized medicine?, Cente...
Can we exploit the power of NGS to move towards personalized medicine?, Cente...
 
Exome sequencing for disease gene identification and patient diagnostics, Gen...
Exome sequencing for disease gene identification and patient diagnostics, Gen...Exome sequencing for disease gene identification and patient diagnostics, Gen...
Exome sequencing for disease gene identification and patient diagnostics, Gen...
 
Introduction to next generation sequencing
Introduction to next generation sequencingIntroduction to next generation sequencing
Introduction to next generation sequencing
 

Similar a Presentatie Prof. de Graaf en Dr. Willems van Dijk

(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석  유전체 정보와 개인라이프로그 정보 활용-2015_11_24(서울의대 공유용) 빅데이터 분석  유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
Hyung Jin Choi
 
Mark Caulfield (Genomics England) - Understanding how genomics will transform...
Mark Caulfield (Genomics England) - Understanding how genomics will transform...Mark Caulfield (Genomics England) - Understanding how genomics will transform...
Mark Caulfield (Genomics England) - Understanding how genomics will transform...
NHShcs
 

Similar a Presentatie Prof. de Graaf en Dr. Willems van Dijk (20)

Clinical proteomics in diseases lecture, 2014
Clinical proteomics in diseases lecture, 2014Clinical proteomics in diseases lecture, 2014
Clinical proteomics in diseases lecture, 2014
 
2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar Cambridge2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar Cambridge
 
"How Scientific Wellness will Drive The Future of Health" - Nathan Price (Pro...
"How Scientific Wellness will Drive The Future of Health" - Nathan Price (Pro..."How Scientific Wellness will Drive The Future of Health" - Nathan Price (Pro...
"How Scientific Wellness will Drive The Future of Health" - Nathan Price (Pro...
 
The Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin WisemanThe Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin Wiseman
 
TDWI STL 20140306 Analytics - Leslie McIntosh
TDWI STL 20140306 Analytics - Leslie McIntoshTDWI STL 20140306 Analytics - Leslie McIntosh
TDWI STL 20140306 Analytics - Leslie McIntosh
 
Biosocial research:How to use biological data in social science research?
Biosocial research:How to use biological data in social science research?Biosocial research:How to use biological data in social science research?
Biosocial research:How to use biological data in social science research?
 
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Mana...
 
MyRISQ
MyRISQMyRISQ
MyRISQ
 
NASH Patient POV with Zobair Younossi, MD
NASH Patient POV with Zobair Younossi, MDNASH Patient POV with Zobair Younossi, MD
NASH Patient POV with Zobair Younossi, MD
 
Comorbidities Present in the Alopecia Areata Registry, Biobank & Clinical Tri...
Comorbidities Present in the Alopecia Areata Registry, Biobank & Clinical Tri...Comorbidities Present in the Alopecia Areata Registry, Biobank & Clinical Tri...
Comorbidities Present in the Alopecia Areata Registry, Biobank & Clinical Tri...
 
Nutrition and HIV: More than 3 decades later
Nutrition and HIV: More than 3 decades laterNutrition and HIV: More than 3 decades later
Nutrition and HIV: More than 3 decades later
 
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석  유전체 정보와 개인라이프로그 정보 활용-2015_11_24(서울의대 공유용) 빅데이터 분석  유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
 
2014 09-08 Personalized healthcare, a view in the near future
2014 09-08 Personalized healthcare, a view in the near future2014 09-08 Personalized healthcare, a view in the near future
2014 09-08 Personalized healthcare, a view in the near future
 
Final FRD
Final FRDFinal FRD
Final FRD
 
Linkedlifelines
LinkedlifelinesLinkedlifelines
Linkedlifelines
 
CNICS: A Great Tool for Outcomes Research
CNICS: A Great Tool for Outcomes ResearchCNICS: A Great Tool for Outcomes Research
CNICS: A Great Tool for Outcomes Research
 
20160119 디지털 헬스케어 의사모임 1월 전체 파일 v3
20160119 디지털 헬스케어 의사모임 1월 전체 파일 v320160119 디지털 헬스케어 의사모임 1월 전체 파일 v3
20160119 디지털 헬스케어 의사모임 1월 전체 파일 v3
 
Mark Caulfield (Genomics England) - Understanding how genomics will transform...
Mark Caulfield (Genomics England) - Understanding how genomics will transform...Mark Caulfield (Genomics England) - Understanding how genomics will transform...
Mark Caulfield (Genomics England) - Understanding how genomics will transform...
 
Ca de endometrio guidelines
Ca de endometrio guidelinesCa de endometrio guidelines
Ca de endometrio guidelines
 
The Foundation of P4 Medicine
The Foundation of P4 MedicineThe Foundation of P4 Medicine
The Foundation of P4 Medicine
 

Más de CVON

Presentatie van Prof. dr.Wilde en Prof. dr. Vos
Presentatie van Prof. dr.Wilde en Prof. dr. VosPresentatie van Prof. dr.Wilde en Prof. dr. Vos
Presentatie van Prof. dr.Wilde en Prof. dr. Vos
CVON
 
presentatie van Prof. dr Rinkel en Prof. dr. Algra
presentatie van Prof. dr Rinkel en Prof. dr. Algrapresentatie van Prof. dr Rinkel en Prof. dr. Algra
presentatie van Prof. dr Rinkel en Prof. dr. Algra
CVON
 

Más de CVON (13)

Presentatie Prof. dr Rinkel en Prof. dr. Algra
Presentatie Prof. dr Rinkel en Prof. dr. AlgraPresentatie Prof. dr Rinkel en Prof. dr. Algra
Presentatie Prof. dr Rinkel en Prof. dr. Algra
 
Presentatie Prof. dr.Wilde en Prof. dr. Vos
Presentatie Prof. dr.Wilde en Prof. dr. VosPresentatie Prof. dr.Wilde en Prof. dr. Vos
Presentatie Prof. dr.Wilde en Prof. dr. Vos
 
Presentatie van Prof. dr.Wilde en Prof. dr. Vos
Presentatie van Prof. dr.Wilde en Prof. dr. VosPresentatie van Prof. dr.Wilde en Prof. dr. Vos
Presentatie van Prof. dr.Wilde en Prof. dr. Vos
 
Presentatie M. Daemen en M. van Buchem
Presentatie M. Daemen en M. van BuchemPresentatie M. Daemen en M. van Buchem
Presentatie M. Daemen en M. van Buchem
 
Presentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsPresentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. Bots
 
Presentatie Prof. dr. Büller en Prof. dr. Reitsma
Presentatie Prof. dr. Büller en Prof. dr. ReitsmaPresentatie Prof. dr. Büller en Prof. dr. Reitsma
Presentatie Prof. dr. Büller en Prof. dr. Reitsma
 
Presentatie Prof. Dr. van Gelder en Prof. Dr. Schotten
Presentatie Prof. Dr. van Gelder en Prof. Dr. SchottenPresentatie Prof. Dr. van Gelder en Prof. Dr. Schotten
Presentatie Prof. Dr. van Gelder en Prof. Dr. Schotten
 
Presentatie Prof. dr. Pinto en Prof. dr. de Windt
Presentatie Prof. dr. Pinto en Prof. dr. de WindtPresentatie Prof. dr. Pinto en Prof. dr. de Windt
Presentatie Prof. dr. Pinto en Prof. dr. de Windt
 
Presentatie Prof. dr. Doevendans en Prof. dr. Clevers
Presentatie Prof. dr. Doevendans en Prof. dr. CleversPresentatie Prof. dr. Doevendans en Prof. dr. Clevers
Presentatie Prof. dr. Doevendans en Prof. dr. Clevers
 
presentatie van Prof. dr Rinkel en Prof. dr. Algra
presentatie van Prof. dr Rinkel en Prof. dr. Algrapresentatie van Prof. dr Rinkel en Prof. dr. Algra
presentatie van Prof. dr Rinkel en Prof. dr. Algra
 
Presentatie van Prof.dr. D. Duncker
Presentatie van Prof.dr. D. DunckerPresentatie van Prof.dr. D. Duncker
Presentatie van Prof.dr. D. Duncker
 
Presentatie van Prof.dr. F. Kuipers
Presentatie van Prof.dr. F. KuipersPresentatie van Prof.dr. F. Kuipers
Presentatie van Prof.dr. F. Kuipers
 
Presentatie Dr. H. Stam, directeur Hartstichting tijdens de 1e bijeenkomst CCVON
Presentatie Dr. H. Stam, directeur Hartstichting tijdens de 1e bijeenkomst CCVONPresentatie Dr. H. Stam, directeur Hartstichting tijdens de 1e bijeenkomst CCVON
Presentatie Dr. H. Stam, directeur Hartstichting tijdens de 1e bijeenkomst CCVON
 

Último

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 

Último (20)

Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 

Presentatie Prof. de Graaf en Dr. Willems van Dijk

  • 1. Cardiobesity Unravelling the mechanistic link between obesity, metabolic disorders and cardiovascular disease Jacqueline de Graaf Ko Willems van Dijk
  • 2. Cardiobesity Consortium Name Institute Genetics Clinical pheno- typing In vitro analysis Animal model Systems Biology Cohorts Intervention Prof. C. van Duijn ErasmusMC X X Prof. J. de Graaf UMCN X X X Dr. K. Willems van Dijk LUMC X X Prof. M. Hofker UMCG X X X X Prof. E. Feskens WUR X X X Prof. P. Slagboom LUMC X X Prof. C. Stehouwer MUMC X X Dr. B. van Ommen TNO X Prof. T. Hankemeier UL X
  • 3. Is it possible to identify those overweight individuals who are prone to developing cardiovascular disease? Cardiobesity Health care problem Age Gender Mechanisms We will reveal novel genes and markers for improved risk stratification, personalized prevention, and new therapeutic options to decrease the CVD burden in the overweight Obesity Metabolic disorders CVD
  • 4. Cardiobesity Research questions What markers/parameters identify those overweight subjects at increased risk for metabolic disorders and CVD WP 6 Genomics platforms and system biology What molecular mechanisms, especially in adipose tissue, are responsible for increased risk for metabolic disorders and CVD? WP1 Genetics WP2 Clinical phenotype WP 4 Molecular mechanisms WP3 Adipose tissue functionality WP 5 Cohorts / Intervention trials Novel candidate genes and markers for CV risk stratification and personalized prevention in overweight individuals
  • 5.
  • 6. Cardiobesity Translation axis Patients: FCH, LLS, cohort subsets Basic and translational research Genetics Clinical phenotyping Systems biology Adipose tissue studies Mouse models Candidate mechanisms: Linking obesity and CVD Epidemiology: Cohorts and interventions Novel candidate genes and markers for CVD risk stratification and personalized prevention in overweight individuals
  • 7. Focus areas Dutch Heart Foundation: Aging Gender Metabolic disorders Cardiobesity Focus areas Obesity Metabolic disorders CVD Age Gender Mechanisms
  • 8. Cardiobesity consortium Unique in combining expertise in basic, clinical and epidemiological research resulting in integrated approach to link obesity to CVD Collaboration with (inter)national consortia: ‘ Complementary and confirmatory replication’ GoNL – BBMRI – NCHA – CHANCES – IDEAL – EAGLE EPI2 - CTMM ‘predict’ - NCSB – CMSB2 – NMC Cardiobesity (Inter)national perspectives
  • 9. To identify those overweight individuals who are prone to develop cardiovascular disease by revealing the mechanisms linking obesity to CVD Cardiobesity Age Gender Mechanisms Obesity Metabolic disorders CVD